CIK细胞联合抗肿瘤药物在原发性肝细胞癌治疗中的进展

原发性肝细胞癌是世界范围内的一种常见疾病,经导管动脉化疗栓塞术(TACE)及手术切除是原发性肝细胞癌的首选治疗方法.但是,手术切除肿瘤复发率高、并发症较多等,栓塞治疗后局部组织缺血、缺氧,促进了血管内皮生长因子的活化,进而促进新生血管形成,导致肿瘤复发,降低疗效,抗肿瘤血管生成治疗能弥补其缺点.CIK细胞可直接杀伤肿瘤细胞,并可增强机体的免疫功能,而成为治疗肿瘤的重要辅助疗法.因此,CIK细胞联合抗血管生成药物成为近年非手术治疗肝细胞癌的热点.

Present development of combination of CIK cell and antitumor drugs in treatment of HCC

Hepatocellular carcinoma(HCC) is a common world wide disease.Surgery and transcatheter arterial chemoembolization(TACE) has been the first choice for these patients.However,surgery has its own limitation such as high relapse rate and high recurrence rate and many complications,what's more,recurrence induced by neovascularization which is stimulated by activation of vascular endothelial growth factors promoted by ischemia and hypoxia in local tissues after the embolization always reduce the effect of treatme...